Antibiotic AM 2282
Protein Kinase Inhibitor
For in vitro use only!
Shipping: shipped on blue ice
Storage Conditions: store at -20 °C
Shelf Life: 12 months
Molecular Formula: C28H26N4O3
Molecular Weight: 466.5 g/mol
Purity: ≥ 98 %
Solubility: 20 mg/ml soluble in DMSO, slightly soluble in Ethanol and Methanol. Insoluble in water.
Staurosporine is a potent cell permeable inhibitor of many kinases including Protein Kinase C, Protein Kinase A, CaM kinase, myosin light chain kinase, and PI3K (IC50 = 9 μM).
The biological effects of Staurosporine include cytotoxicity, relaxation of smooth muscle, and regulation of eNOS gene expression. It inhibits platelet aggregation induced by collagen or ADP but has no effect on thrombin-induced platelet aggregation.
Staurosporine induces apoptosis in human malignant glioma cell lines and arrests normal cells at the G1 checkpoint.
Walker et al. (2000) Structural Determinants of Phosphoinositide 3-Kinase Inhibition by Wortmannin, LY294002, Quercetin, Myricetin, and Staurosporine. Mol. Cell. 6:909.
Wan et al. (2002) PTEN augments staurosporine-induced apoptosis n PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ. 9:414.
Lee et al. (2000) Divergent effects of protein kinase C (PKC) inhibitors staurosporine and bisindolylmaleimide I (GF109203X) on bone resorption. Biochem. Pharmacol. 60:923.
Takano (1994) Staurosporine inhibits STA2-induced platelet aggregation by inhibition of myosin light-chain phosphorylation in rabbit washed platelets. Ann. N. Y. Acad. Sci. 714:315.
Matsumoto et al. (1989) Staurosporine a protein kinase C inhibitor interferes with proliferation of arterial smooth muscle cells. Biochem. Biophys. Res. Comm. 158:105.